Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long-Term Follow-Up of Hospitalized Dengue and Safety in Thai Children Who Were Included in an Efficacy Study of a Tetravalent Dengue Vaccine

Next Previous
Trial Profile

Long-Term Follow-Up of Hospitalized Dengue and Safety in Thai Children Who Were Included in an Efficacy Study of a Tetravalent Dengue Vaccine

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CYD TDV (Primary) ; Rabies vaccine
  • Indications Dengue
  • Focus Therapeutic Use
  • Sponsors Sanofi

    • Most Recent Events

    • 04 Apr 2021 Results of post-hoc analysis assessing hospitalized and severe VCD cases over the entire six-year follow-up of (two Phase III trials (CYD14 [NCT01373281] and CYD15 [NCT01374516]) and the Phase IIb trial (CYD23/CYD57 [NCT00842530/NCT01983553]) published in the Clinical Infectious Diseases
    • 13 Jun 2018 Results of post-hoc analysis assessing effect of dengue serostatus on vaccine safety and efficacy by using data from four trials including this trial published in the New England Journal of Medicine.
    • 27 Sep 2016 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top